Floatz logo

Durvalumab

Liver Metastasis Colon Cancer

University of Iowamonoclonal_antibodyPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Liver Metastasis Colon Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Fudan University
Phase 4BBB
Fruquintinib
Peking University
Phase 3BBB
DEXAMETHASONE
Fudan University
Phase 3BB
Capecitabine
Jun Huang
Phase 3BB
Irinotecan
Jun Huang
Phase 3BB

View all 50 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →